89 related articles for article (PubMed ID: 22280805)
1. Phase II study of hypofractionated image-guided radiotherapy for localized prostate cancer: outcomes of 55 Gy in 16 fractions at 3.4 Gy per fraction.
Wu JS; Brasher PM; El-Gayed A; Pervez N; Tai PT; Robinson J; Skarsgard D; Joseph K; Sia MA; Pearcey RG
Radiother Oncol; 2012 May; 103(2):210-6. PubMed ID: 22280805
[TBL] [Abstract][Full Text] [Related]
2. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
3. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma.
Martin JM; Rosewall T; Bayley A; Bristow R; Chung P; Crook J; Gospodarowicz M; McLean M; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1084-9. PubMed ID: 17606331
[TBL] [Abstract][Full Text] [Related]
5. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
[TBL] [Abstract][Full Text] [Related]
6. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.
Madsen BL; Hsi RA; Pham HT; Fowler JF; Esagui L; Corman J
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1099-105. PubMed ID: 17336216
[TBL] [Abstract][Full Text] [Related]
8. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
[TBL] [Abstract][Full Text] [Related]
9. Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer.
Leborgne F; Fowler J; Leborgne JH; Mezzera J
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1200-7. PubMed ID: 21477933
[TBL] [Abstract][Full Text] [Related]
10. Late outcomes following hypofractionated conformal radiotherapy vs. standard fractionation for localized prostate cancer: a nonrandomized contemporary comparison.
Leborgne F; Fowler J
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1441-6. PubMed ID: 19395194
[TBL] [Abstract][Full Text] [Related]
11. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
King CR; Brooks JD; Gill H; Pawlicki T; Cotrutz C; Presti JC
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1043-8. PubMed ID: 18755555
[TBL] [Abstract][Full Text] [Related]
13. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
14. Image guided hypofractionated radiotherapy and quality of life for localized prostate cancer: prospective longitudinal study in 337 patients.
Jereczek-Fossa BA; Santoro L; Zerini D; Fodor C; Vischioni B; Dispinzieri M; Bossi-Zanetti I; Gherardi F; Bonora M; Caputo M; Vavassori A; Cambria R; Garibaldi C; Cattani F; Matei DV; Musi G; De Cobelli O; Orecchia R
J Urol; 2013 Jun; 189(6):2099-103. PubMed ID: 23313200
[TBL] [Abstract][Full Text] [Related]
15. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
Kupelian PA; Willoughby TR
Cancer J; 2001; 7(5):421-6. PubMed ID: 11693901
[TBL] [Abstract][Full Text] [Related]
16. Accelerated hypofractionated adjuvant whole breast radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients.
Cante D; Rosa La Porta M; Casanova-Borca V; Sciacero P; Girelli G; Pasquino M; Franco P; Ozzello F
Breast J; 2011; 17(6):586-93. PubMed ID: 21951485
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
Lim TS; Cheung PC; Loblaw DA; Morton G; Sixel KE; Pang G; Basran P; Zhang L; Tirona R; Szumacher E; Danjoux C; Choo R; Thomas G
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):85-92. PubMed ID: 18355982
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated radiotherapy with or without IGRT in prostate cancer: preliminary report of acute toxicity.
Valeriani M; Monaco F; Osti MF; DE Sanctis V; Minniti G; Enrici RM
Anticancer Res; 2011 Oct; 31(10):3555-8. PubMed ID: 21965777
[TBL] [Abstract][Full Text] [Related]
19. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
Peeters ST; Heemsbergen WD; van Putten WL; Slot A; Tabak H; Mens JW; Lebesque JV; Koper PC
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1019-34. PubMed ID: 15752881
[TBL] [Abstract][Full Text] [Related]
20. Treating intermediate-risk prostate cancer with hypofractionated external beam radiotherapy alone.
Faria S; Dal Pra A; Cury F; David M; Duclos M; Freeman CR; Souhami L
Radiother Oncol; 2011 Dec; 101(3):486-9. PubMed ID: 21864925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]